NCT03715504: Phase I Study of TP-3654 in Patients With Advanced Solid Tumors

NCT03715504
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with presence of symptomatic central nervous system metastatic disease that requires treatment – see trial for details
https://ClinicalTrials.gov/show/NCT03715504

Comments are closed.

Up ↑